Expressions of TRPC5 and miR-320a in thyroid cancer and their clinical significances_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 PANG Chang’an ¹ , ZHU Honghai ² , LI Xuejuan ¹ , LI Hongqiang ³

1. Department of Otorhinolaryngology, Head and Neck Surgery, Zhengzhou Seventh People’s Hospital, Zhengzhou 450006, P. R. China;
2. Department of Rhinology, The First Clinical Medical College of Zhengzhou University, Zhengzhou 450052, P. R. China;
3. Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, P. R. China;

Corresponding author：

PANG Chang’an, Email: panm8011@163.com

Keywords：

thyroid cancer; transient receptor potential channel C5; microRNA-320a; clinicopathologic features; prognosis

DOI：

10.7507/1007-9424.202011099

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To detect expressions of transient receptor potential channel C5 (TRPC5) and microRNA-320a (miR-320a) in thyroid cancer and explore clinical significances of them in thyroid cancer.Methods The expressions of TRPC5 and miR-320a mRNA in the thyroid cancer were investigated by searching the Ualcan database. While the expressions of TRPC5 and miR-320a mRNA in 80 cases of thyroid cancer, 35 cases of thyroid adenoma and 32 cases of normal thyroid tissues adjacent to thyroid adenoma tissues in the Zhengzhou Seventh People’s Hospital from March 2014 to March 2015 were tested. Real time PCR was used to detect the expressions of TRPC5 mRNA and miR-320a mRNA in the various tissues and Western blot was used to detect the TRPC5 protein in the thyroid cancer tissues. Therelationships between the expressions of TRPC5 and miR-320a mRNAs and clinicopathologic features of thyroid cancer were analyzed. The correlation between expressions of TRPC5 and miR-320a mRNA was analyzed by Pearson method. The risk factors influencing the prognosis were analyzed by univariate and multivariate Cox proportional hazards regression model.Results The results of Ualcan database showed that the expression level of TRPC5 mRNA in the thyroid cancer was higher than that in the normal thyroid tissue (P<0.001), while the expression level of miR-320a mRNA was lower than that in the normal thyroid tissue (P<0.001). The results of clinical cases showed that the expression level of TRPC5 mRNA was significantly higher, while the expression of miR-320a mRNA was significantly lower in the thyroid cancer tissues as compared with the normal thyroid tissues (P<0.05). There was a negative correlation between the expression level of TRPC5 and miR-320a mRNA in the thyroid cancer (r=−0.653, P<0.001). The expressions of TRPC5 and miR-320a mRNA were correlated with the degree of differentiation, lymph node metastasis, and TNM stage (P<0.05). Kaplan-Meier survival curve analysis found that the patients with higher expression level of TRPC5 and lower expression level of miR-320a showed the poor prognosis, and multivariate analysis found that the lower tumor differentiation, later TNM stage, with lymph node metastasis, higher expression level of TRPC5 mRNA, and lower expression level of miR-320a mRNA were the risk factors affecting prognostic survival (P<0.05).Conclusions From the database and clinical case data, it is concluded that TRPC5 mRNA is highly expressed, while miR-320a mRNA is lowly expressed in thyroid cancer tissues, and expressions of TRPC5 and miR-320a mRNA are related to degree of tumor differentiation, lymph node metastasis, TNM staging, and prognosis in patients with thyroid cancer. TRPC5 and miR-320a mRNA might be used as potential indicators for clinical and prognostic monitoring.

Citation： PANG Chang’an, ZHU Honghai, LI Xuejuan, LI Hongqiang. Expressions of TRPC5 and miR-320a in thyroid cancer and their clinical significances. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(9): 1165-1170. doi: 10.7507/1007-9424.202011099 Copy

1.	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin, 2017, 67(1): 7-30.
2.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
3.	Ancker OV, Krüger M, Wehland MI, et al. Multikinase inhibitor treatment in thyroid cancer. Int J Mol Sci, 2019, 21(1): 10.
4.	魏涛, 朱精强. p53 基因家族与甲状腺癌的相关研究进展. 中国普外基础与临床杂志, 2019, 26(11): 1372-1377.
5.	延常姣, 黄美玲, 肖晶晶, 等. 甲状腺癌相关多原发癌的临床及病理特征分析. 现代肿瘤医学, 2020, 28(1): 40-43.
6.	Tankeu AT, Ndip Agbor V, Noubiap JJ. Calcium supplementation and cardiovascular risk: A rising concern. J Clin Hypertens (Greenwich), 2017, 19(6): 640-646.
7.	傅倩云, 朱瑞宇, 方罗, 等. 下调 TRPC5 的表达对卵巢癌细胞耐药性影响的研究. 中国细胞生物学学报, 2019, 41(4): 681-687.
8.	石少敏, 赵建军, 于杜鹃, 等. miR-320a 靶向 Rab11a 调控非小细胞肺癌细胞增殖的研究. 中国实验诊断学, 2018, 22(9): 1636-1638.
9.	程莹星, 黄勇, 张丽娟, 等. 乳腺癌组织中 miR-320a 的表达及意义. 山东医药, 2018, 58(25): 20-22.
10.	李雨珊, 张仁静, 周雪梅, 等. 微小 RNA-181a-5P、320a 及其靶基因 TGF-β1 在食管鳞癌中的表达. 肿瘤预防与治疗, 2019, 32(5): 395-401.
11.	余长云, 李金映, 曹华. 基于数据挖掘分析 NETO2 基因在头颈鳞癌中的表达及临床意义. 现代肿瘤医学, 2019, 27(18): 3223-3225.
12.	Yapa S, Mulla O, Green V, et al. The role of chemokines in thyroid carcinoma. Thyroid, 2017, 27(11): 1347-1359.
13.	Iglesias ML, Schmidt A, Ghuzlan AA, et al. Radiation exposure and thyroid cancer: a review. Arch Endocrinol Metab, 2017, 61(2): 180-187.
14.	Ren H, Shen Y, Hu D, et al. Co-existence of BRAF^V600E and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis. Cancer Manag Res, 2018, 10: 1005-1013.
15.	Lu JY, Cheng WC, Chen KY, et al. Using ion torrent sequencing to study genetic mutation profiles of fatal thyroid cancers. J Formos Med Assoc, 2018, 117(6): 488-496.
16.	张浩, 孙威. 长链非编码 RNA 与甲状腺癌发生发展关系的研究进展及其临床价值. 中国普外基础与临床杂志, 2018, 25(10): 1161-1164.
17.	He DX, Ma X. Transient receptor potential channel C5 in cancer chemoresistance. Acta Pharmacol Sin, 2016, 37(1): 19-24.
18.	Chen Z, Zhu Y, Dong Y, et al. Overexpression of TrpC5 promotes tumor metastasis via the HIF-1α-Twist signaling pathway in colon cancer. Clin Sci (Lond), 2017, 131(19): 2439-2450.
19.	荀瑞峰, 鲁厚根, 汪献旺. CDC25C 在肝癌中的表达及其意义. 重庆医学, 2020, 49(4): 633-637.
20.	刘欢, 李红昌, 陈亚峰, 等. 微小 RNA 在三阴性乳腺癌中的研究进展. 中国普外基础与临床杂志, 2020, 27(1): 103-106.
21.	Xie F, Yuan Y, Xie L, et al. miRNA-320a inhibits tumor proliferation and invasion by targeting c-Myc in human hepatocellular carcinoma. Onco Targets Ther, 2017, 10: 885-894.
22.	Chen Z, Tang C, Zhu Y, et al. TrpC5 regulates differentiation through the Ca²⁺/Wnt5a signalling pathway in colorectal cancer. Clin Sci (Lond), 2017, 131(3): 227-237.
23.	刘亚群, 张秀珑, 张志华, 等. miR-320a 与肺部恶性肿瘤相关性的研究进展. 河北北方学院学报(自然科学版), 2020, 36(2): 58-60.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin, 2017, 67(1): 7-30.
2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
3. Ancker OV, Krüger M, Wehland MI, et al. Multikinase inhibitor treatment in thyroid cancer. Int J Mol Sci, 2019, 21(1): 10.
4. 魏涛, 朱精强. p53 基因家族与甲状腺癌的相关研究进展. 中国普外基础与临床杂志, 2019, 26(11): 1372-1377.
5. 延常姣, 黄美玲, 肖晶晶, 等. 甲状腺癌相关多原发癌的临床及病理特征分析. 现代肿瘤医学, 2020, 28(1): 40-43.
6. Tankeu AT, Ndip Agbor V, Noubiap JJ. Calcium supplementation and cardiovascular risk: A rising concern. J Clin Hypertens (Greenwich), 2017, 19(6): 640-646.
7. 傅倩云, 朱瑞宇, 方罗, 等. 下调 TRPC5 的表达对卵巢癌细胞耐药性影响的研究. 中国细胞生物学学报, 2019, 41(4): 681-687.
8. 石少敏, 赵建军, 于杜鹃, 等. miR-320a 靶向 Rab11a 调控非小细胞肺癌细胞增殖的研究. 中国实验诊断学, 2018, 22(9): 1636-1638.
9. 程莹星, 黄勇, 张丽娟, 等. 乳腺癌组织中 miR-320a 的表达及意义. 山东医药, 2018, 58(25): 20-22.
10. 李雨珊, 张仁静, 周雪梅, 等. 微小 RNA-181a-5P、320a 及其靶基因 TGF-β1 在食管鳞癌中的表达. 肿瘤预防与治疗, 2019, 32(5): 395-401.
11. 余长云, 李金映, 曹华. 基于数据挖掘分析 NETO2 基因在头颈鳞癌中的表达及临床意义. 现代肿瘤医学, 2019, 27(18): 3223-3225.
12. Yapa S, Mulla O, Green V, et al. The role of chemokines in thyroid carcinoma. Thyroid, 2017, 27(11): 1347-1359.
13. Iglesias ML, Schmidt A, Ghuzlan AA, et al. Radiation exposure and thyroid cancer: a review. Arch Endocrinol Metab, 2017, 61(2): 180-187.
14. Ren H, Shen Y, Hu D, et al. Co-existence of BRAF^V600E and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis. Cancer Manag Res, 2018, 10: 1005-1013.
15. Lu JY, Cheng WC, Chen KY, et al. Using ion torrent sequencing to study genetic mutation profiles of fatal thyroid cancers. J Formos Med Assoc, 2018, 117(6): 488-496.
16. 张浩, 孙威. 长链非编码 RNA 与甲状腺癌发生发展关系的研究进展及其临床价值. 中国普外基础与临床杂志, 2018, 25(10): 1161-1164.
17. He DX, Ma X. Transient receptor potential channel C5 in cancer chemoresistance. Acta Pharmacol Sin, 2016, 37(1): 19-24.
18. Chen Z, Zhu Y, Dong Y, et al. Overexpression of TrpC5 promotes tumor metastasis via the HIF-1α-Twist signaling pathway in colon cancer. Clin Sci (Lond), 2017, 131(19): 2439-2450.
19. 荀瑞峰, 鲁厚根, 汪献旺. CDC25C 在肝癌中的表达及其意义. 重庆医学, 2020, 49(4): 633-637.
20. 刘欢, 李红昌, 陈亚峰, 等. 微小 RNA 在三阴性乳腺癌中的研究进展. 中国普外基础与临床杂志, 2020, 27(1): 103-106.
21. Xie F, Yuan Y, Xie L, et al. miRNA-320a inhibits tumor proliferation and invasion by targeting c-Myc in human hepatocellular carcinoma. Onco Targets Ther, 2017, 10: 885-894.
22. Chen Z, Tang C, Zhu Y, et al. TrpC5 regulates differentiation through the Ca²⁺/Wnt5a signalling pathway in colorectal cancer. Clin Sci (Lond), 2017, 131(3): 227-237.
23. 刘亚群, 张秀珑, 张志华, 等. miR-320a 与肺部恶性肿瘤相关性的研究进展. 河北北方学院学报(自然科学版), 2020, 36(2): 58-60.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Expressions of TRPC5 and miR-320a in thyroid cancer and their clinical significances

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content